START AND STAY WITH BRIVIACT FOR
THEIR LONG-TERM JOURNEY
5-year long-term retention and SGTC seizure freedom data available1,2
BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.3
RETENTION
One year after beginning BRIVIACT, an estimated 8 out of 10 patients were still on treatment2
KAPLAN-MEIER ESTIMATE OF PERCENTAGE OF ADULT PATIENTS REMAINING ON TREATMENT IN A POOLED STUDY2
Adapted from Toledo et al, 2016.
Five years post initiation, more than half of patients were still taking BRIVIACT, as estimated in the study2
- Patients who discontinued for reasons other than lack of efficacy or adverse events were censored from the analysis2
- This retention data is an estimation of how long patients remained on BRIVIACT in select studies. Conclusions of long-term efficacy or safety should not be drawn based on this data2
- Limited exposure was seen at the later time points; 41 patients (1.7%) continued treatment for ≥8 years, and 3 patients (0.1%) continued for ≥8.5 years2
Study design2
- Adult patients with epilepsy from phase 2b and phase 3 trials, uncontrolled by 1-3 ASMs
- Patients continued into an open-label, long-term, follow-up trial, taking BRIVIACT 50-200 mg/day (N=2,051)
This long-term retention data is an estimation of how long patients have remained on treatment in select BRIVIACT clinical studies.
ASM=antiseizure medication.
EFFICACY
The established efficacy of BRIVIACT provides a strong treatment foundation
Efficacy was established in adult trials without a titration period3
PERCENT REDUCTION (BRIVIACT ADJUNCTIVE THERAPY OVER PLACEBO) IN FOCAL SEIZURE FREQUENCY ADJUSTED TO 28 DAYS DURING THE TREATMENT PERIOD3
Across all 3 trials, low discontinuation rates due to
adverse events were observed3:
- Placebo: 4%
- BRIVIACT 50 mg/day: 5%
- BRIVIACT 100 mg/day: 8%
- BRIVIACT 200 mg/day: 7%
Pivotal trial design3
- Effectiveness was established in 3 fixed-dose, randomized, double-blind, placebo-controlled, multicenter studies with a 12-week treatment period, and comprised 1,550 adult patients
- Enrolled adult patients had focal seizures that were not adequately controlled by 1 to 2 concomitant ASMs
- Patients taking concomitant levetiracetam were excluded from Study 3
ASM=antiseizure medication.
SGTC SEIZURE FREEDOM
Patients with ~3 SGTCS per 28 days at baseline achieved SGTC seizure freedom in the short and long term1,4
SHORT-TERM (12-WEEK) SGTC SEIZURE FREEDOM RATE FROM A POOLED POST HOC ANALYSIS4
SGTCS=secondarily generalized tonic-clonic seizure.
LONG-TERM (5 YEARS)
More than 1 in 3 patients overall (35%) experienced zero SGTC seizures for at least one year during the long-term follow-up post hoc analysis1
More patients achieved seizure freedom for a year or more when BRIVIACT was started earlier, according to long-term data5
PATIENTS WITH ≥1 YEAR SGTC SEIZURE FREEDOM AT ANY TIME DURING THE LONG-TERM (5-YEAR) FOLLOW-UP POST HOC ANALYSIS5
Study design
- 12 weeks: Post hoc analysis of patients with SGTC seizures among their baseline seizures from pooled data of three Phase 3 pivotal trials4
- 5 years: Post hoc analysis conducted to evaluate the efficacy and tolerability of long-term BRIVIACT treatment in patients ≥16 years of age who reported SGTCS during the 8-week baseline of three Phase 3 pivotal trials and received adjunctive BRIVIACT in either the pivotal trials or the long-term follow up1
- Efficacy (concomitant levetiracetam excluded) and tolerability (concomitant levetiracetam included) were assessed on the first day of BRIVIACT in patients who initiated BRIVIACT at 50-200 mg/day1
DOSING
BRIVIACT offers simple 1:1 dose conversion between formulations3
Products not shown at actual size.
- Dose adjustments are recommended for patients with all stages of hepatic impairment3
- When BRIVIACT is co-administered with rifampin, an increase in the BRIVIACT dose is recommended3
PK PROFILE
BRIVIACT exhibits a linear and time-independent pharmacokinetic profile3
UCB provides multiple resources for eligible patients starting on BRIVIACT
Learn more about savings & support